Zannad, Faiez

Electronic health records to facilitate clinical research

Cowie, M. R., Blomster, J. I., Curtis, L. H., Duclaux, S., Ford, I., Fritz, F., Goldman, S., Janmohamed, S., Kreuzer, J., Leenay, M., et al. (2017) · Clinical Research in Cardiology

Electronic Health Records SystemsMedical Coding and Health Information

Cited by 651

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal

Hormonal Regulation and HypertensionRenin-Angiotensin System Studies

Cited by 638

Mannheim intima-media thickness consensus

Touboul, P.-J., Hennerici, M. G., Meairs, S., Adams, H., Amarenco, P., Desvarieux, M., Ebrahim, S., Fatar, M., Hernandez Hernandez, R., Kownator, S., et al. (2004) · Cerebrovascular Diseases

Cardiovascular Health and Disease PreventionCerebrovascular and Carotid Artery Diseases

Cited by 594

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Mentz, R. J., Kelly, J. P., von Lueder, T. G., Voors, A. A., Lam, C. S. P., Cowie, M. R., Kjeldsen, K., Jankowska, E. A., Atar, D., Butler, J., et al. (2014) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 546

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 435

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 352

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Zannad, F., Anker, S. D., Byra, W. M., Cleland, J. G. F., Fu, M., Gheorghiade, M., Lam, C. S. P., Mehra, M. R., Neaton, J. D., Nessel, C. C., et al. (2018) · New England Journal of Medicine

Heart Failure Treatment and ManagementAtrial Fibrillation Management and Outcomes

Cited by 345

Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure

Swedberg, K., Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J., & Pitt, B. (2012) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 313

Vascular Structure and Function Is Correlated to Cognitive Performance and White Matter Hyperintensities in Older Hypertensive Patients With Subjective Memory Complaints

Kearney-Schwartz, A., Rossignol, P., Bracard, S., Felblinger, J., Fay, R., Boivin, J.-M., Lecompte, T., Lacolley, P., Benetos, A., & Zannad, F. (2009) · Stroke

Cardiovascular Health and Disease PreventionDementia and Cognitive Impairment Research

Cited by 274

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 264

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 231

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations

Rogers, J. K., McMurray, J. J. V., Pocock, S. J., Zannad, F., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., & Pitt, B. (2012) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 224

Health in times of uncertainty in the eastern Mediterranean region, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013

Mokdad, A. H., Forouzanfar, M. H., Daoud, F., El Bcheraoui, C., Moradi-Lakeh, M., Khalil, I., Afshin, A., Tuffaha, M., Charara, R., Barber, R. M., et al. (2016) · The Lancet Global Health

Health and Conflict StudiesGlobal Health and Epidemiology

Cited by 220

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Butler, J., Filippatos, G., Jamal Siddiqi, T., Brueckmann, M., Böhm, M., Chopra, V. K., Pedro Ferreira, J., Januzzi, J. L., Kaul, S., Piña, I. L., et al. (2022) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 206

Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial

Sarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., Nodari, S., Konstam, M., Swedberg, K., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 202

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 183

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal

Diabetes Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 152

Patient selection in heart failure with preserved ejection fraction clinical trials

Kelly, J. P., Mentz, R. J., Mebazaa, A., Voors, A. A., Butler, J., Roessig, L., Fiuzat, M., Zannad, F., Pitt, B., O’Connor, C. M., et al. (2015) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 139

Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes

Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 131

Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency

Damman, K., Tang, W. H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H., & McMurray, J. J. V. (2014) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 122

Empagliflozin and major renal outcomes in heart failure

Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 112

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

Packer, M., Butler, J., Zeller, C., Pocock, S. J., Brueckmann, M., Ferreira, J. P., Filippatos, G., Usman, M. S., Zannad, F., & Anker, S. D. (2023) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 86

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial

Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 85